Davis Polk advised Capio AB (publ) on its initial public offering and listing of shares on NASDAQ Stockholm. Assuming full exercise of the overallotment option, 52,934,872 shares were sold in total, of which 15,463,918 shares were sold by Capio AB and 32,658,693 shares were sold by Capio’s primary shareholders through Ygeia Equity AB, a company owned by entities controlled by funds managed by the private equity firms Nordic Capital, Apax Europe and Apax France, at an offer price of SEK 48.5 per share, raising gross proceeds of SEK2.5 billion (US$300 million).

Capio is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services through its hospitals, specialist clinics and primary care units. In 2014, Capio’s 12,357 employees provided healthcare services during 4.6 million patient visits across the Group’s facilities in Sweden, Norway, France and Germany, generating net sales of SEK13.2 billion (US$1.6 billion). Capio’s medical strategy is to have an empowered organization drive quality improvements by implementing new, evidence-based medical methods aimed at reducing the physical strain of treatment and helping patients to make a faster recovery.    

The Davis Polk corporate team advising as to U.S. and English law included partner Paul E. Kumleben and associates Matt Hart and Johanna R. Collins-Wood advising as to U.S. law and associate Nathan Lee advising as to English law. Partner John D. Paton and associate Nicholas A. Machen provided tax advice. Members of the Davis Polk team are based in the London office. 

Copy link to share post